title: Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
abstract: The objective of this study was to determine the therapeutic ratio of fractionated radiolabeled immunoglobulin therapy (RIT) for patients with recurrent Hodgkin's disease. Ninety patients with recurrent Hodgkin's disease received 2 mg of yttrium-90-labeled polyclonal rabbit antihuman ferritin IgG i.v. Fifty-seven patients received a single (unfractionated) administration per treatment cycle; 11 of them were treated with 0.3 mCi/kg body weight, 39 were treated with 0.4 mCi/kg body weight, and 7 received 0.5 mCi/kg body weight per treatment cycle. Thirty-three patients had their radiolabeled immunoglobulin administration separated (fractionated) in 2 x 0.25 mCi/kg body weight (total activity, 0.5 mCi/kg). The interval between fractions was 1 week. Radioimmunoconjugates did not cause serious acute side effects. In vivo radioimmunoconjugates were stable. Human antirabbit IgG antibodies were found in 2 of 50 retreated patients (<5%). Hematological toxicity was the only side effect noted in all patients, and it was usually temporary. Response rates (RRs) were 20%, 61%, and 86% after 0.3, 0.4, or 0.5 mCi/kg unfractionated yttrium-90-labeled antiferritin. The RR for patients treated with fractionated RIT was 42%. In the fractionated RIT group, complete responses were decreased, and progressive disease increased (P < 0.05). Complete responses had a medium duration of 6 months. Median survival times were 390 days for 1 x 0.4 mCi/kg and 300 days for the 2 x 0.25 mCi/kg patient group. Fractionation did not provide the expected decrease in hematological toxicity or the expected increase in tumor RRs.
authors.affiliation: Arlington Cancer Center, Texas 76012, USA. hvriesendo@aol.com
authors.forename: H M
authors.initials: HM
authors.lastname: Vriesendorp
authors.forename: S M
authors.initials: SM
authors.lastname: Quadri
authors.forename: C T
authors.initials: CT
authors.lastname: Wyllie
authors.forename: J
authors.initials: J
authors.lastname: Lai
authors.forename: P E
authors.initials: PE
authors.lastname: Borchardt
authors.forename: L
authors.initials: L
authors.lastname: Harris
authors.forename: R
authors.initials: R
authors.lastname: Wucher
authors.forename: E
authors.initials: E
authors.lastname: Askew
authors.forename: L
authors.initials: L
authors.lastname: Schweichler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D019583:Dose Fractionation, Radiation; D005260:Female; D005293:Ferritins / Q000276:immunology*; D006689:Hodgkin Disease / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011786:Quality Control; D011817:Rabbits; D016499:Radioimmunotherapy / Q000009:adverse effects; D012008:Recurrence
chemical_list: D005293:Ferritins